Tumor growth curves showed improved tumor control for TILT-517 + anti-PD-1 or anti-PD-L1 compared to their ICIs monotherapy alternatives (Figures 7C and 7D), and the combination with anti-PD-L1 displayed highly significant differences (p < 0.0001). The gene discussed is CD274; the disease is neoplasm.